Latest News

• Upcoming webinar!        

  Our next webinar will take place on Monday, November 10, 2025 at 1pm ET. The topic is "Molecular Work-Up and Therapeutic Targeting of H3K27M-Diffuse Midline Glioma" with Dr. Carl Koschmann. To join, visit virtualtrials.org/webinar. 

  
  
• NuvOx and FYR Bio Announce NCI Funding for Liquid Biopsy Collaboration Supporting NuvOx's Phase IIb Glioblastoma Trial        

  NanO₂ is an investigational therapy being developed by NuvOx for newly diagnosed glioblastoma (GBM). It helps deliver oxygen into low-oxygen (hypoxic) tumor regions, making radiation more effective. It's given intravenously (just before each radiation session). The ongoing Phase IIb RESTORE trial for this therapy completed enrollment of 87 patients last month, and the company was recently awarded NIH/NCI funding to support advanced liquid biopsy work within the Phase IIb trial. We're glad to see this therapy advancing and hope to see positive results from the RESTORE trial within the next year.

  
  
• Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting        

   Final results from Novocure's Phase 3 METIS trial show that tumor treating fields (TTFields), when used after stereotactic radiosurgery (SRS) for brain metastases from non-small cell lung cancer (NSCLC), significantly delays intracranial progression compared to best supportive care alone. Patients receiving TTFields plus best supportive care had a median time to intracranial progression of 15 months, versus 7.5 months for the control group, with no negative impact on quality of life or neurocognition. For patients who received immune checkpoint inhibitors in addition to TTFields, the benefit was even more pronounced. While overall survival and neurocognitive outcomes were similar between groups, TTFields was well tolerated, with primarily low-grade skin-related side effects. Based on these results, Novocure plans to apply for FDA approval of TTFields for brain metastases from NSCLC. 

  
  
• Innovative system accurately detects genetic mutations in the brain tumor within 25 minutes        

  Researchers in Japan have developed a new, ultra-fast system (GeneSoc®-based rapid phenotyping system) that can detect key genetic mutations in brain tumors in under 25 minutes. Their research, recently published in Neuro-Oncology, showed that the system exhibits high diagnostic accuracy, with 98.5% sensitivity and 98.2% specificity for detection of ID1 mutations, as well as 100% sensitivity and specificity for detection of TERT promoter mutations. This system may not only be effective for assisting with rapid diagnosis, but also for detecting tumor boundaries intraoperatively. While clinical adoption of this type of technology may take time, this is a promising step forward.